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Abstract
Background Diabetes is a chronic condition and when
poorly controlled can lead to complications and death.
Patients with glycated hemoglobin (A1C) measures[9 %
are at significant risk for diabetes-related complications
impacting the patient’s quality of life and imposing higher
costs on the healthcare system. A1C reductions of 1 % or
greater in this population have demonstrated substantial
health and economic benefits. Reducing the percent of
patients at risk is an essential component of quality-care
measures established for patients with diabetes.
Objective To evaluate if switching patients prescribed
subcutaneous insulin injections to V-Go for insulin deliv-
ery would impact clinical and economic parameters in
patients with poorly controlled diabetes (A1C[ 9 %).
Methods The study was a retrospective analysis using data
extracted from the electronic medical records database of a
multicenter diabetes system. Outcome measures included
mean change in A1C from baseline, the percent of patients
achieving a reduction in A1C C1 % while on V-Go ther-
apy, and the impact to quality measures. In addition, eco-
nomic analyses were conducted to assess the pharmacy
budget impact and projected implication to total healthcare
cost.
Results Ninety-seven patients were evaluated after a mean
duration of 13.6 ± 6.9 weeks of insulin delivery with
V-Go. Switching to V-Go resulted in an overall mean
change (95 % CI) in A1C of -2.0 % (-1.7 to -2.3;
p\ 0.001) from a baseline of 10.5 %. Seventy-three per-
cent of patients achieved an A1C reduction C1 %. Cost
analysis supported a direct pharmacy savings of $119.30
(18.80–219.60, p = 0.020) per patient per month compared
with baseline.
Conclusion Switching to V-Go for insulin delivery resul-
ted in significant glycemic improvement and proved cost
effective. This real-world assessment could be applied
more broadly at the health system and plan level.
Key Points
Modest improvements in A1C levels can reduce the
onset and/or progression of complications in patients
with diabetes at high risk and may ease the burden of
total healthcare costs.
Insulin therapy is conventionally delivered by
subcutaneous injections and is often prescribed for
patients with poorly controlled diabetes; however,
over 30 % of patients remain poorly controlled
despite insulin injections. This lack of control brings
to light the need for decision makers to evaluate if
new insulin delivery alternatives offer advantages for
improving glycemic control.
V-Go, a new disposable insulin delivery device
proved beneficial for the patient, payer, and plan
through improved glycemic control and reduced
direct pharmacy costs. Furthermore, positive
implications to HEDIS measures and Star Ratings
were likely secondary to 71 % of this high-risk
population achieving an A1C B 9 %.
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1 Introduction
Diabetes-related complications including cardiovascular
disease, kidney disease, neuropathy, blindness, and lower-
extremity amputation contribute significantly to increased
morbidity and mortality among patients with diabetes, and
dramatically affect healthcare expenditures [1]. Evidence
shows that patients with poor glycemic control
(A1C[ 9.0 %) are at high risk for long-term complica-
tions [2–4]. Decreasing this risk is an established priority as
demonstrated by quality performance measures. The
Healthcare Effectiveness Data and Information Set (HEDIS
measures), one of the most widely used sets of healthcare
performance measure in the USA and the Star rating sys-
tem used by Medicare both have negative scoring impli-
cations for patients with A1C measurements[9 %.
Costs related to diabetes have been reported to be two to
eight times higher in poorly controlled patients or those
with diabetes complications [5, 6]. Between 2007 and
2012, the national economic burden grew by 40 % for
diagnosed diabetes, with diabetes complications account-
ing for more than 35 % of the estimated US$91.8 billion in
direct medical expenditures [7]. Medications as a whole
represent over one-quarter (28 %) of all health expendi-
tures attributed to diabetes healthcare cost [7]. Improving
glycemic control as defined by diabetes quality measures
can delay the onset and progression of diabetes complica-
tions resulting in improved quality of life for patients and a
decreased cost burden to healthcare systems.
A positive correlation has been validated between gly-
cemic markers and the risk for complications in patients
with type 2 or type 1 diabetes. In the United Kingdom
Prospective Diabetes Study (UKPDS), each 1 % reduction
in A1C was associated with a decrease in risk of 37 % for
microvascular complications, a 14 % lower rate of
myocardial infarction, and a 21 % reduction in deaths
associated to diabetes [8]. In the Diabetes Control and
Complications Trial (DCCT), a 10 % reduction in A1C
decreased the risk for retinopathy progression by 40–50 %
[9]. Achieving these glycemic reductions in patients who
are less controlled typically requires insulin.
Insulin is regarded as one of the most potent agents
available to address hyperglycemia when non-insulin glu-
cose-lowering medications (NIGLM) fail to maintain or
improve control. However, greater than 30 % of patients
remain poorly controlled despite being prescribed insulin
[10]. Establishing an understanding as to why persistent
hyperglycemia exists despite insulin therapy is essential to
improving care. Evaluating whether the prescribed insulin
regimen provides adequate coverage to match glycemic
fluctuations is an essential first step as insulin secretion
from the pancreas is limited with disease progression.
Secondly, the assessment of insulin adherence can provide
valuable insight when efficacy expectations fall short.
Studies have demonstrated the complexity of a regimen
and the desire to avoid embarrassment from injecting
insulin in public can contribute to insulin non-adherence
and have a negative impact on efficacy [11–13]. Missing
the equivalent of four mealtime injections per week for
3 months has been correlated with a 0.92 % increase in
A1C [14]. Prescribed insulin regimens should provide
sufficient glycemic coverage and address adherence
obstacles to improve patient outcomes.
V-Go Disposable Insulin Delivery device is a wearable
device for adult patients requiring insulin. V-Go provides a
simple method to offer basal-bolus insulin delivery to
cover both fasting and postprandial glucose excursions
with one application per 24 h. V-Go is filled with U-100
fast acting insulin, applied to the skin and with the push of
a button inserts a 4.6-mm 30-gauge stainless steel needle
subcutaneously, which initiates delivery of a continuous
preset basal rate of insulin for 24 h. Mealtime insulin
coverage is achieved by the simple push of two buttons
sequentially [15]. Insulin delivery with V-Go has been
associated with improved glycemic control across a wide
range of patient demographics and has been demonstrated
to be a more cost-effective method of basal-bolus insulin
delivery when compared to multiple daily injections of
insulin [16–19]. However, to our knowledge, data are
lacking pertaining to the impact of V-Go in a high-risk
patient population.
The purpose of this analysis was to evaluate the impact
on both glycemic measures and costs for patients with poor
glycemic control despite being prescribed subcutaneous
insulin injections, switched to V-Go for insulin delivery.
2 Methods
2.1 Data Source and Study Description
Data for this retrospective analysis were extracted from the
electronic medical record (EMR) database of Diabetes
America, a specialized diabetes system including 13 com-
prehensive centers located across the state of Texas, USA.
A systematic search using keywords identified potential
patients switched to V-Go between 1 April 2013 and 31
October 2014, and patient charts were then reviewed using
study inclusion and exclusion criteria to determine study
eligibility. Patients were managed per clinician standard of
care including timing and frequency of follow-up visits and
medication management. The study protocol was reviewed
and approved by Allendale IRB, and a waiver of informed
consent was approved.
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2.2 Patient Selection
Inclusion criteria required: (1) patients diagnosed with
diabetes mellitus (type 1, type 2, or LADA); (2) age equal
to or greater than 21 years; (3) baseline A1C between 9 and
14 % (within 6 weeks of V-Go initiation); (4) previously
prescribed basal or basal-bolus insulin therapy with or
without NIGLM, and switched to V-Go for insulin deliv-
ery; and (5) a minimum of one subsequent A1C laboratory
value on V-Go therapy. Patients were excluded for: (1)
history of treatment with U-500 insulin preceding V-Go
initiation or the non-US Food and Drug Administration
(FDA)-approved utilization of U-500 insulin in V-Go; (2)
administration of insulin via an insulin pump immediately
preceding V-Go initiation; (3) pregnancy or lactation; (4)
undeterminable insulin dosing due to insufficient chart in-
formation; or (5) a history of pancreatic cancer.
2.3 Data Collection
Clinical and demographic data were extracted from the
EMR at baseline and for the first follow-up visit when an
A1C value was captured. Clinical data extracted for this
analysis included A1C values, prescribed insulin, NIGLM,
body weight, body mass index (BMI), co-morbidities, and
patient-reported hypoglycemic events.
Insulin is commonly prescribed utilizing a range in
dose to allow additional units for insulin therapy opti-
mization (titration, correction, sliding scale). The total
allowable insulin dose was used for all clinical and eco-
nomic evaluations. The mode of delivery (insulin pen,
vial, and syringe, V-Go) and insulin brand were collected
and accounted for to provide an accurate economic
assessment.
Concomitant NIGLM were recorded before and during
the evaluation period. All prescribed NIGLM were cap-
tured by dose, brand, and class and included biguanides,
dipeptidyl peptidase-4 inhibitors, GLP-1 receptor agonists,
sodium glucose linked transporter-2 inhibitors, sulfony-
lureas, thiazolidinediones, and combinations of these drug
classes. Patients were grouped based on evidence of an
increase, decrease, or no change to baseline diabetes
medications at the follow-up visit. Only those increases or
decreases to concomitant medications where adequate time
had elapsed for the medication change to impact clinical
outcomes were considered. An addition or removal of a
medication, qualified as a change in concomitant medica-
tions. Patients with both an addition and removal of med-
ication were not grouped for further sub-analyses.
The principal investigator oversaw review of subject
records to determine study eligibility and data collection.
Records from all sites were reviewed via the EMR data-
base. Clinical results were collected and included in this
study analysis through the first follow-up A1C result on
V-Go or 31 March 2015, whichever occurred first.
2.4 Study Measures
This study was designed to specifically evaluate a high-risk
diabetes population. Clinical evaluations included change in
glycemic control measured by A1C and change in insulin
total daily dose (TDD) from baseline with additional con-
sideration for changes to NIGLM. Further analyses per-
taining to glycemic control were conducted to assess the
percentage of patients achieving an A1C reduction C1 %
and those achieving an A1C B 9 % while on V-Go therapy.
Direct diabetes-related pharmacy costs before V-Go and on
V-Go were calculated to assess cost impact to the pharmacy
budget. All insulin costs were normalized by calculating a
30-day insulin requirement based on the total allowable
prescribed TDD and multiplying monthly insulin dose in
units by the unit cost of the prescribed insulin. Costs asso-
ciated with mode of insulin delivery (pen needles, syringes
or V-Go) were also included. All changes to concomitant
NIGLM were captured; however, only changes encom-
passing branded medications were accounted for in phar-
macy cost calculations. Costs of all glucose lowering
medications were based on published wholesale acquisition
costs (WAC) in 2015 US dollars [20]. We further sought to
determine the projected annualized impact to total health-
care costs by using an established economic model for
patients achieving an A1C reduction of C1 %.
2.5 Statistical Analysis
Descriptive analysis (mean, percentage, standard deviation)
were performed for all baseline characteristics. Repeated-
measure t-tests were used to assess the changes in A1C,
insulin, and cost variables from baseline for all patients as
well as differences based on changes to NIGLM. Subgroup
comparisons based on increases, decreases, or no changes
to NIGLM were performed using ANOVA for continuous
variables and chi-square tests and Fisher’s exact test for
categorical variables. A between-group sensitivity analysis
for change in A1C and insulin was conducted with a one-
factor analysis of covariance (ANCOVA) model with the
factor based on change to NIGLM and the baseline cor-
responding variable as a covariate.
3 Results
3.1 Study Population
Baseline characteristics are shown in Table 1 for 97
patients who had been switched from subcutaneous insulin
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injections to V-Go and met eligibility requirements. The
mean ± SD duration of diabetes for this high-risk popu-
lation was 13.8 ± 8.7 years with a baseline A1C of
10.51 ± 1.08 % and weight of 98 ± 22 kg. Over 60 % of
the studied population had a duration of diabetes
C10 years. All patients were administering insulin at
baseline, with the majority prescribed basal-bolus therapy
and diagnosed with multiple underlying co-morbidities.
3.2 Clinical Effectiveness
Regardless of insulin regimen at baseline, significant A1C
reductions were observed with V-Go and the incidence of
patient-reported hypoglycemia remained similar to base-
line. Change in mean A1C is shown in Fig. 1. Following a
mean of 13.6 ± 6.9 weeks using V-Go for insulin delivery,
mean ± SD A1C was 8.48 ± 1.20 % (p\ 0.001). An
A1C reduction of C1 % was achieved by 73 % of patients
(71 out of 97 patients) and nearly three-quarters (71 %)
achieved an A1C B 9 %. Over one-third (36 %) of the
total patients achieved an A1C B 8 %. Evaluation of A1C
distribution for this high-risk population before and on
V-Go is represented in Fig. 2.
In addition to significant improvements in A1C, there
were significant reductions in total insulin requirements.
Switching to V-Go resulted in an overall mean change
(95 % CI) in TDD of -39.1 units/day (-28.7 to -49.6;
p\ 0.001) from a baseline of 98.7 units/day. Insulin TDD
based on units/kg changed from 1.02 ± 0.57 to
0.60 ± 0.17 units/kg/day; p\ 0.001. Patients administer-
ing basal-only insulin regimens were prescribed 62.8 ± 36
units/day prior to V-Go and were able to decrease total
insulin requirements to 56.1 ± 15.1 units/day, p = 0.275.
For patients administering a basal-bolus insulin regimen at
baseline, a 49 % reduction in TDD with V-Go was
observed from a baseline of 119.9 ± 58.4 units/day,
p\ 0.001.
Changes made to NIGLM while on V-Go therapy were
evaluated to determine whether changes in clinical
parameters (A1C control and insulin dose) were influenced
by these changes. Fifty-two patients had no change to
concomitant NIGLM, 23 patients had an increase, 16
patients had a decrease, and six patients had both an
increase and a decrease to NIGLM based on the informa-
tion available in patient charts. Clinical findings based on
change to NIGLM are shown in Figs. 1 and 3 and Table 2.
All groups demonstrated a significant reduction in A1C
from baseline (p\ 0.001) irrespective of changes to con-
comitant NIGLM. Sensitivity analyses were conducted
based on change in NIGLM using a model adjusted for
Table 1 Baseline characteristics
N = 97
Clinical characteristics Mean [SD]
Weight, kg 98 [22]
BMI, kg/m2 34 [8]
A1C, % 10.51 [1.08]
A1C range, % 9.1–13.4
Duration of diabetes 13.8 [8.7]
Age, years 54 [12]
Age range, years 25–88
Patient characteristics N (%)
Type 2 diabetes 83 (86)




African American 28 (29)
Undetermined 5 (5)






Coronary artery disease 14 (14)
Renal disease 9 (9)
Peripheral vascular disease 6 (6)
Congestive heart failure 1 (1)
Glucose-lowering medications N (%)
Prescribed insulin 97 (100)
Basal-bolus insulin regimen 61 (63)
Basal insulin regimen 36 (37)











A1C glycated hemoglobin, BMI body mass index, kg per m2 kilo-
grams per square meter, DPP-4I dipeptidyl peptidase-4 inhibitor,
GLP-1RA glucagon-like peptide-1 receptor agonist, Met metformin,
SD standard deviation, SGLT-2I sodium-glucose linked transporter-2
inhibitor, TZD thiazolidinedione
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baseline A1C to calculate change in A1C. These findings
were similar to the primary results with an adjusted mean
(SE) change of -2.02 ± 0.30 for those with no change
compared to -1.95 ± 0.25 and -2.02 ± 0.30 for those
with an increase or decrease, respectively. Differences in
A1C reductions were not significant (p = 0.983) between
any group when compared to each other. A model adjusting
for baseline insulin doses was used to compare insulin
reductions between patients where no change was made to
NIGLM and for those where an increase in NIGLM was
made. A significant between-group difference of -12
units/day (p = 0.003) was demonstrated favoring those
with no change in concomitant medications.
In light of the high percentage (86 %) of patients
diagnosed with type 2 diabetes and the potential role of
insulin resistance, changes to therapeutic agents known to
address insulin resistance were further evaluated for clini-
cal relevance to findings. Metformin dosing was consistent
between baseline and follow-up (1600 mg/day) with no
apparent clinical relevance on the findings. Thiazolidine-
dione (TZD) dosing also remained similar to baseline;
however, the percentage of patients prescribed TZD
increased from three to six patients. Greater A1C reduc-
tions (-3.3 % from baseline) were observed for patients
prescribed TZD along with a mean insulin TDD reduction
of 30 units/day.
3.3 Economic Impact
Direct diabetes-related pharmacy costs before and on V-Go
are shown in Table 3. There were significant reductions in
direct pharmacy costs while improving glycemic control
with V-Go insulin delivery (Fig. 4). Cost savings are dis-
cussed as per patient per month (PPPM) and per patient per
quarter (PPPQ) using actual prescription data and medi-
cation changes as recorded in the EMR. V-Go use across
the patient population resulted in a direct PPPM and PPPQ
mean pharmacy cost savings (95 % CI) of $119.30
(18.80–219.60; p = 0.020) and $358.00 (57.00–658.00;
p = 0.020), respectively. Direct pharmacy savings were
also realized across all patients stratified by change in
concomitant NIGLM. In those patients where the only
therapeutic change was the switch to V-Go for insulin
delivery, pharmacy costs were reduced significantly by
15 % (p = 0.017).
Additional medical cost reductions are probable given
the level of glycemic improvement. An established eco-
nomic model published by Wagner et al. [21] projects A1C
























No Change in NIGLM 
Increase in NIGLM 
Decrease in NIGLM 
Fig. 1 Change in A1C. *p\ 0.001 compared to baseline for each
group (all patients—10.51 %, no change—10.47 %, increase—
10.83 %, decrease—10.29 %). Data are given as means. A1C































On V-Go A1C (%) 
6      7      8      9     10      11    12     13     14 
6      7      8      9     10      11    12    13    14 
Fig. 2 Change in A1C distribution. A1C distribution before V-Go
and after 13.6 weeks on V-Go. A1C glycated hemoglobin
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healthcare cost savings of $1169 (± 10 %; range $1052–
$1286) per patient based on 2011 US dollars. Applying this
model to the 71 patients (73 %) experiencing an A1C
reduction of C1 % in this analysis would equate to a pro-
jected annualized total healthcare savings of $82,999
($74,692–$91,306).
4 Discussion
Increased healthcare costs and resource utilization can be
expected for patients with poor glycemic control. In addi-
tion, poor A1C control may impact the performance of the
health plan and how the plan measures against national and
regional benchmarks. A longer duration of diabetes
increases the likelihood of poor glycemic control. Patients
with diabetes for 10 or more years have been shown to be
more than nine times as likely to have poor control com-
pared to patients with 3 years or less [22]. As the disease
progresses and the physiological processes are disrupted,
Fig. 3 Change in insulin dose *p\ 0.001 compared with before
V-Go therapy for each group. Data are given as means. NIGLM non-
insulin glucose-lowering medication, TDD insulin total daily dose
Table 2 Comparisons based on changes to non-insulin glucose-lowering medication(s)
On V-Go











A1C, % mean [SD] 8.53 [1.0] 8.58 [1.4] 0.871 8.50 [1.3] 0.927
A1C reduction C1 %, n (%) 38 (73) 17 (74) 0.940 11 (69) 0.736
A1C B 9 %, n (%) 38 (73) 16 (70) 0.755 10 (62) 0.417
Glucose-lowering medications
Insulin, mean [SD]
TDD units/day mean [SD] 55 [15] 72 [16]a \0.001 57 [12] 0.499
Basal units/day mean [SD] 32 [8] 42 [11]a \0.001 34 [8] 0.343
Non-insulin agentsb, n (%)
Metformin 16 (31) 12 (52) 0.077 11 (69) 0.007
Sulfonylurea 5 (10) 2 (9) 0.90 0 (0) 0.198
GLP-1RA 6 (12) 8 (35) 0.017 2 (13) 0.917
DPP-4I 3 (6) 1 (4) 0.801 0 (0) 1.0
DPP-4I/metformin 3 (6) 2 (9) 0.639 0 (0) 1.0
TZD 0 (0) 5 (22) 0.001 0 (0) –
SGLT-2I 0 (0) 6 (26) \0.001 0 (0) –
Met/sulfonylurea 1 (2) 0 (0) 1.0 0 (0) 1.0
Pioglitazone/sulfonylurea 0 (0) 0 (0) – 0 (0) –
DPP-4I/pioglitazone 0 (0) 1 (4) 1.0 0 (0) –
A1C glycated hemoglobin, DPP-4I dipeptidyl peptidase-4 inhibitor, GLP-1RA glucagon-like peptide-1 receptor agonist, Met metformin, NIGLM
non-insulin glucose-lowering medications, SD standard deviation, SGLT-2I sodium-glucose linked transporter-2 inhibitor, TDD insulin total
daily dose, TZD thiazolidinedione
a Includes supplemental basal insulin for 5 patients (mean 21 units/day) and supplemental bolus insulin for 2 patients (mean 15 units/day)
b Multiple agents per patient possible
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treating patients with persistent hyperglycemia can be
challenging.
Evidence supports that even modest glycemic reductions
can prevent deaths from complications related to diabetes
and A1C reductions of C1 % have proven instrumental in
decreasing the onset and/or progression of complications
having a positive effect on total medical costs. Better
adherence to diabetes medications has been associated with
a 13 % reduction in the risk of hospitalization or a visit to
the emergency room [23]. It has been projected that greater
medication adherence can reduce the annual medical
spending per patient by $4413 for adults and by $5170 for
patients C65 years of age [24].
Insulin is widely used and a proven therapeutic agent for
patients with diabetes; however, one-third of patients remain
uncontrolled despite insulin therapy. New advancements in
insulin delivery support glycemic lowering and improve
adherence through easing the burden of insulin therapy.
History informs us that embracing advancements of this
nature have proved beneficial as the conversion of insulin
delivery from a vial and syringe to an insulin pen was
associated with improved adherence resulting in signifi-
cantly fewer hypoglycemic events, reduced emergency
department and physician visits, and lower annual treatment
costs [25]. V-Go is simple to use and provides convenient
and discreet administration of basal-bolus insulin delivery.
This study was designed to reflect real-world diabetes
management and to evaluate the clinical and economic
impact of V-Go a new disposable insulin delivery device
for insulin delivery in a poorly controlled patient popula-
tion. Based on the long duration of diabetes in the majority
of patients studied, insulin production by the pancreas was
likely limited. A high probability exists that prescribed
baseline insulin regimens were either insufficient to pro-
vide full glucose coverage or considered complex by the
patient, thus negatively affecting adherence. Switching
insulin delivery from subcutaneous injections to V-Go
provided patients with a 24-h efficient and continuous basal
rate of insulin and the option for mealtime dosing with only
one application per 24 h.
Table 3 Direct diabetes-related pharmacy costs














Pharmacy costs PPPMa PPPM
Non-insulin agentsb $175.60 $203.00 $104.50 $433.10 $80.10
Insulin TDD costsc $788.80 $403.00 $369.90 $487.40 $386.90
Syringe/pen needlesd $24.49 $0.63 $2.34
V-Go device – $262.94 $262.94 $262.94 $262.94
Total therapy costs $988.89 $869.57 $737.34 $1185.78 $729.94
NIGLM non-insulin glucose-lowering medications, PPPM per patient per month, TDD insulin total daily dose, WAC wholesale acquisition costs
a Costs based on WAC pricing (US $) for specific brand and dose of medication
b Costs not included for generic medications (metformin, sulfonylurea, and metformin/sulfonylurea)
c Insulin costs are normalized by multiplying the prescribed TDD in units by the unit price and converted to a 30-day monthly cost
d Syringe/pen needles based on 1/day for patients administering basal only insulin and 3/day for patients administering multiple daily injections
before V-Go and as applicable for supplemental insulin using V-Go
Fig. 4 Direct diabetes-related pharmacy savings on V-Go. Savings
are based on WAC pricing and calculated from subtracting total
diabetes-related mean costs on V-Go from the baseline diabetes-
related mean costs before V-Go for each group. Savings repre-
sented in US dollars and rounding was applied. NIGLM non-insulin
glucose-lowering medication, PPPM per patient per month, PPPQ
per patient per quarter, WAC wholesale acquisition costs
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In less than 4 months, mean A1C levels were signifi-
cantly reduced, utilizing 40 % less insulin, and 73 % of
patients achieved an A1C reduction of C1 % on V-Go.
These improvements are impressive considering aggressive
pharmacological interventions had previously been pre-
scribed to this population and switching to V-Go for insulin
delivery was the only therapeutic change in the majority of
patients. We attribute glycemic improvements to efficient
and appropriate insulin coverage as well as improved
adherence to mealtime dosing as additional preparation
processes are not required with V-Go to administer meal-
time insulin and the insulin can be delivered discreetly.
These opinions are based on the fact that even patients
prescribed multiple daily subcutaneous injections at base-
line demonstrated a mean A1C reduction of 1.8 ± 1.6 %
once switched to V-Go.
Cost implications to the payer and plan were positively
impacted. Direct diabetes-related pharmacy costs were
significantly reduced with V-Go. Furthermore, improve-
ments to the A1C distribution for the patient population on
V-Go could have far reaching implications for the
improvement of quality metrics as both HEDIS and Star
ratings encourage targeted initiatives to improve the quality
of care and reduce the percent of patients with A1C mea-
surements [9 %. Reimbursement rates and ratings for
elderly Medicare patients from CMS to health insurers are
higher if A1C levels are improved below these thresholds.
Physician pay for performance initiatives by health plans
and the medical home model have been initiated as an
effort to improve diabetes care. Prior to V-Go therapy the
patient population presented here had not achieved diabetes
targets despite aggressive pharmacologic intervention.
Switching to V-Go resulted in 71 % of patients achieving
glycemic targets B9 %. With additional time and insulin
optimization further improvement and benefit should be
expected.
There are limitations to this analysis. First and foremost,
this was a short-term retrospective study and did not
include a parallel control group. The analysis population
served as their own control with changes compared from
baseline. A careful review was performed to identify
patients switched to V-Go to ensure there was no sample
selection bias. Secondly, cost calculations were based on
prescribed medications documented in the medical records
and may not be reflective of actual adherence and fulfill-
ment may have differed. Thirdly, to be included in the
analysis patients were required to have at least one follow-
up office visit with an A1C result recorded so the data in
our study may not be representative of all patients initiating
V-Go therapy and may be influenced by patients with a
propensity to adhere to medication. Finally, the prevalence
of actual hypoglycemia may have differed as patient self-
reporting was used in the findings. These data represent
real-world experience with no educational initiatives, spe-
cial procedures, trainings and/or practice changes imple-
mented during the study period that could have contributed
to the results. The data recording process was consistent
across baseline and on V-Go.
5 Conclusions
This study supports the effectiveness of V-Go, a new
alternative for insulin delivery, in patients with poor gly-
cemic control at high risk. Significant reductions in A1C,
insulin doses, and direct pharmacy costs were all observed
after switching to V-Go. These findings are reflective of
clinical care practice in a real-world setting and could be
applied more broadly at the health system and plan level.
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